Compare EXPI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | STOK |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | EXPI | STOK |
|---|---|---|
| Price | $9.03 | $31.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $12.00 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 980.2K | 875.5K |
| Earning Date | 02-19-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $4,678,653,000.00 | $205,632,000.00 |
| Revenue This Year | $6.03 | $430.24 |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | ★ N/A | $46.47 |
| Revenue Growth | 5.12 | ★ 1128.17 |
| 52 Week Low | $6.90 | $5.35 |
| 52 Week High | $12.23 | $38.69 |
| Indicator | EXPI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 25.25 | 51.79 |
| Support Level | $9.55 | $31.00 |
| Resistance Level | $9.94 | $33.90 |
| Average True Range (ATR) | 0.29 | 1.67 |
| MACD | -0.12 | -0.26 |
| Stochastic Oscillator | 4.80 | 17.61 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.